About Theralytix™

Theralytix was established in 2020 by its founders, who have decades of professional medical and scientific experience in the business space. We recognize a significant opportunity in global markets for our products. The products consist of naturally-occurring agents for killing selected strains of bacteria.

Since its founding Theralytix has developed broad spectrum bacteriophage products that deploy bacteriophages active against multiple strains of pathogenic bacteria in the following genera: Salmonella, Shigella, Pseudomonas, Escherichia, Staphylococcus, Streptococcus, Enterococcus, Proteus, Klebsiella and Acinetobacter.

While Theralytix will initially manufacture branded products for human use, the phage components will be made available to third parties for use in all verticals.